LinqMed
Chiba, Japan· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
Japanese radiopharmaceutical startup developing copper-64-based theranostic agents for visible cancer diagnosis and treatment.
Oncology
Technology Platform
Copper-64 (⁶⁴Cu) radioisotope-based theranostic platform enabling both PET imaging and targeted radiotherapy through a single radiopharmaceutical agent.
Opportunities
Growing radiopharmaceutical market with increasing adoption of theranostic approaches; potential for copper-64 platform to address limitations of current radioisotopes; Japanese government support for deep-tech startups.
Risk Factors
Early-stage company with unproven clinical candidates; competition from established radiopharmaceutical companies; regulatory challenges for novel radioisotope therapies; dependence on specialized manufacturing and supply chain for copper-64.
Competitive Landscape
Competes with Novartis (Lutathera, Pluvicto) and other radiopharmaceutical developers, but differentiates through copper-64 theranostic platform offering combined imaging and treatment capabilities from a single agent.